The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
(Approval lapsed) RYTHMODAN disopyramide 100mg Capsules (UK)
Section 19A approved medicine
(Approval lapsed) RYTHMODAN disopyramide 100mg Capsules (UK)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Expired
Medicines in short supply/unavailable
RYTHMODAN disopyramide 100 mg capsule blister pack - ARTG 13537
Indication(s)
Rythmodan capsules are indicated for the management of documented ventricular arrhythmias, such as sustained ventricular tachycardia, which are judged to be life threatening. Because of its proarrhythmic potential, the use of disopyramide is not recommended for lesser arrhythmias.
Treatment of asymptomatic ventricular premature contractions should be avoided.
In patients with structural heart disease, proarrhythmia and cardiac decompensation are a special risk associated with antiarrhythmic medicines. Special caution should be exercised when prescribing disopyramide for these patients.
Images
